Yox1 links MBF-dependent transcription to completion of DNA synthesis

Blanca Gómez-Escoda, Tsvetomira Ivanova, Isabel A. Calvo, Isabel Alves-Rodrigues, Elena Hidalgo & José Ayte* Oxidative Stress and Cell Cycle Group, Universitat Pompeu Fabra, Barcelona, Spain

When DNA replication is challenged cells activate a DNA synthesis checkpoint, blocking cell cycle progression until they are able to overcome the replication defects. In fission yeast, Cds1 is the effector kinase of this checkpoint, inhibiting M-phase entry, stabilizing stalled replication forks and triggering transcriptional activation of S-phase genes. The molecular basis of this last effect is largely unknown. The Mlu1 binding factor (MBF) complex controls the transcription of S-phase genes. We purified novel interactors of the MBF complex and identified the repressor Yox1. When the DNA synthesis checkpoint is activated, Yox1 is phosphorylated, which abrogates its binding to MBF. MBF-dependent transcription therefore remains active until cells are able to overcome this challenge.

Keywords: DNA synthesis checkpoint; HU; MBF; S-phase transcription

INTRODUCTION

Checkpoints recognize damaged DNA or blocks to replication and delay cell-cycle progression by inhibiting cell-cycle machinery until the problem is resolved (Hartwell & Weinert, 1989; Elledge, 1996; Rhind & Russell, 1998). Fission yeast Cds1 is the effector kinase of the DNA synthesis checkpoint (Murakami & Okayama, 1995; Boddy & Russell, 1999) and has an essential role in arresting cells before M phase through phosphorylation and/or inhibition of the essential phosphatase Cdc25. It also maintains DNA replication fork stability when a replication fork stalls, through phosphorylation of several proteins including Mus81-Eme1, Rqh1 and Rad60 (Boddy et al, 1998; Rhind & Russell, 2000; Kai & Wang, 2003). These processes allow cells to survive replication challenges by preventing stalled replication forks from degenerating into defective DNA structures and blocking cell-cycle progression. Thus, cells are arrested until they are able to overcome the replication defects by inducing a transcriptional induction of S-phase genes that helps to re-start the replication machinery.

The activity of the transcription factor Mlu1 binding factor (MBF)—a multimeric complex containing at least Cdc10, Res1 and Res2—is required for the completion of Start in Schizosaccharomyces pombe (Lowndes et al, 1992; Caligiuri & Beach, 1993). MBF—the functional homologue of mammalian E2F/RB—drives the G1–S wave of transcription, controlling the expression of some genes that are directly or indirectly required for DNA synthesis, such as cdc18 and cdt1—which code for proteins that bind replication origins as well as cdc22 (ribonucleotide reductase; Lowndes et al, 1992; Ayte et al, 2001). Therefore, control of MBF activity is essential to ensure normal cell-cycle progression. MBF is bound to its target promoters throughout the cell cycle (Wuarin et al, 2002), suggesting that MBF activity is not due to modulation of its DNA-binding activity. Interestingly, two MBF targets—the cyclin Cig2 and the co-repressor Nrm1—have been implicated in negative feedback loops that could explain, at least partly, how MBF-dependent transcription is inactivated at the end of S phase (Ayte et al, 2001; de Bruin et al, 2008). In this work, we demonstrate a direct link between the DNA synthesis checkpoint and the S-phase transcriptional programme on a single protein, Yox1, which couples both events. Furthermore, phosphorylation of Yox1 when the checkpoint kinase is activated triggers the transcriptional induction of the S-phase genes.

RESULTS AND DISCUSSION

Yox1 is a repressor of the MBF complex

To elucidate the mechanism by which MBF is regulated, we purified the native MBF complex and characterized the proteins that interact physically with this transcription factor. We combined immunoprecipitation with isobaric tags for relative and absolute quantification (Ross et al, 2004) followed by liquid chromatography, tandem mass spectrometry (LC/MS/MS) (supplementary Fig S1A,B online). Cdc10-associated proteins were purified from cells expressing haemagglutinin-tagged Cdc10 from its chromosomal locus using a haemagglutinin antibody. We used an untagged wild-type strain as a control. The most enriched proteins in the purification were Cdc10, Res1, Res2, as expected, and a homeodomain-containing protein encoded by a nonessential open reading frame (SPBC21B10.13c), recently named Yox1 due to its sequence homology to budding yeast Yox1 (Aigliani et al, 2009). By using specific antibodies, we detected a reciprocal in vivo interaction between Yox1 and Cdc10 (supplementary Fig S1C online), which is dependent on
Yox1 is a substrate of the DNA synthesis checkpoint. (A) Total RNA was prepared from untreated (−) or HU-treated (+) cultures (3 h at 30 °C) of wild-type and Δyox1 cells, and analysed by hybridization with the indicated probes. his3 and rRNA are shown as loading controls. (B) Mitotic chromosome stability assay (minichromosome Ch16 loss) of wild-type and Δyox1 strains were measured as the percentage of colonies with a red sector (Ade−). The average (± s.d.) of four experiments is shown. (C) Serial dilutions of wild-type, Δyox1, Δcdd1 and Δyox1 Δcdd1 strains were spotted on agar plates without (YES5) or with 2 mM HU, and grown for 3 days at 30 °C. (D) Extracts prepared from untreated (−) or HU-treated (+) cultures of a strain expressing Yox1-13Myc were resolved in an 8% SDS–PAGE and western blotted to detect Yox1. (E) Antibodies to detect Yox1. (F) Extracts from untreated (−) or HU-treated (+) cultures from strains expressing Yox1-13Myc were analysed to detect Yox1 phosphorylation. (G) Extracts from untreated (−) or HU-treated (+) cultures from strains expressing Yox1-13Myc (wild-type) or the mutants S114A (SA), T115A (TA), S114A T115A (SATA) or S6AS114A T115A (SASATA), were analysed to detect Yox1 phosphorylation. HA, haemagglutinin; HU, hydroxyurea; SDS–PAGE, sodium dodecyl sulphate–polyacrylamide gel electrophoresis; λ PPase, λ-phosphatase; WT, wild-type.

intact MBF complex; in the absence of Res1 or Res2, Yox1 was not able to bind to Cdc10 (supplementary Fig S1D online).

Next, we wanted to determine whether Yox1 had an effect on MBF regulation. We prepared RNA from wild-type and Δyox1 cells, either from asynchronous cultures or from cells arrested in S phase with hydroxyurea. There was an overall increase in the level of MBF-dependent transcription in Δyox1 cells, as measured by the amount of cdc18 mRNA (Fig 1A). The effect of Yox1 on MBF-dependent transcription was confirmed in synchronous cultures, as they progressed from a G2–M block (supplementary Fig S2 online). Thus, whereas a cdc25-22 strain was able to induce the expression of cdc18 immediately after release and in the subsequent G1–S phase, a cdc25-22 Δyox1 strain had high levels of cdc18 expression throughout the time-course. yox1 expression is also dependent on MBF (Aligianni et al, 2009; Dutta & Rhind, 2009).

Despite having a cell-cycle-dependent regulated transcription, Yox1 protein was detected during two complete cell cycles, with minor changes at the level of protein concentration and with constitutive nuclear localization (supplementary Fig S3A–C online), indicating that post-translational modification of Yox1 could have a role in the regulation of its activity. In fact, despite its presence in the nucleus throughout the cell cycle, the timing of Yox1 association with Cdc10 promoter during the cell cycle fits with inactivation of MBF-dependent transcription (supplementary Fig S3D online), indicating that Yox1 has a negative role in the regulation of MBF-dependent transcription.

Cells in which yox1 has been deleted show minor cell-cycle defects, such as a slight delay in cytokinesis, producing larger cells than wild type during septation (Aligianni et al, 2009). As Δyox1 cells have an increased transcription of all the
MBF-dependent genes and deregulated transcription has an effect on the functionality of yeast centromeres (Kagansky et al., 2009), we aimed to determine the effect of the lack of Yox1 on chromosome segregation. We noticed that Dyox1 cells were genomically unstable, shown by an increased rate (six-fold) of chromosome loss (0.35% in Dyox1 cells compared with 0.06% in wild-type cells; Fig 1B). Dcds1 cells are hypersensitive to hydroxyurea, even in low doses (Fig 1C). We hypothesized that cells with a mutation on yox1 (Dyox1) could compensate for the absence of a DNA synthesis checkpoint in Dcds1 cells by maintaining upregulated MBF-dependent transcription. Thus, when Δyox1 Δcds1 cells were challenged in the presence of low doses of hydroxyurea, they were more resistant to the drug than Δcds1 cells (Fig 1C).

**Yox1 is a target of the DNA synthesis checkpoint**

While treating cells with hydroxyurea, we noticed that Yox1 changed its mobility (Fig 1D). To determine whether this was due to phosphorylation, extracts were treated with l-phosphatase, resulting in a shift to the faster migrating form (Fig 1E). These observations led us to investigate whether Yox1 is a substrate of the effector kinase Cds1 (Boddy et al., 1998). In support of this, we
observed no change in the mobility of Yox1 in 
and 
yox1 or in 
cells after hydroxyurea treatment (Fig 1F). Yox1 has two putative Cds1 phosphorylation sites (LXRXXS/T) on Ser 114 and Thr 115 (Seo et al. 2003; Xu & Kelly, 2009). When both sites were mutated to alanine (SATA), the Yox1 mobility shift of hydroxyurea-treated extracts was almost abolished (Fig 1G, lanes 2 and 8). Conversely, Yox1 also has a CDK phosphorylation site on Ser 6. Substitution of this serine with alanine (S6A) resulted in a substrate that could not be phosphorylated in vitro by Cdc2 or Cdc13 (supplementary Fig S4 online). Further inclusion of the Ser 6 mutation in Yox1.SATA (SASATA) completely inhibited the mobility shift observed in hydroxyurea-treated cells (Fig 1G, lanes 9 and 10). We concluded that while Ser 6 is the single target of CDK, Ser 114 and Thr 115 are the direct or indirect targets of the Cds1 pathway. We demonstrated a physical interaction between MBF and Yox1 in asynchronously growing cells (supplementary Fig S1C,D online), but when Yox1 was phosphorylated as a consequence of the activation of the DNA synthesis checkpoint after hydroxyurea treatment, this interaction was lost (Fig 2A, lanes 5 and 6; Fig 2B). Nevertheless, this interaction was preserved in cells in which this Cds1-dependent phosphorylation was abrogated, because they expressed a mutant Yox1 that cannot be phosphorylated (Yox1.SATA; Fig 2A, lanes 7 and 8).

Although single mutations (Yox1.SA or Yox1.TA) had a strong effect on Yox1 mobility (Fig 1G), the effect on MBF-dependent transcription after hydroxyurea treatment was minor. However, Yox1.SATA cells had severely impaired MBF-dependent induction of transcription when treated with hydroxyurea (Fig 2C,D), without affecting the normal cell-cycle regulation of MBF-dependent genes (supplementary Fig S5 online). Thus, Yox1 phosphorylation on Ser 114 and Thr 115 was the single event required to activate MBF-dependent transcription when the checkpoint was activated until DNA synthesis machinery was replenished with deoxynucleotides. Concomitantly with the loss of interaction between Yox1 and MBF after treatment with hydroxyurea, Yox1 is evicted from hydroxyurea-treated cells (supplementary Fig S5 online). Further inclusion of the Ser 6 mutation in Yox1.SATA (SASATA) completely inhibited the mobility shift observed in hydroxyurea-treated cells (Fig 2C, lanes 5 and 8). Conversely, Yox1 also has a CDK phosphorylation site on Ser 6. Substitution of this serine with alanine (S6A) resulted in a substrate that could not be phosphorylated in vitro by Cdc2 or Cdc13 (supplementary Fig S4 online). Further inclusion of the Ser 6 mutation in Yox1.SATA (SASATA) completely inhibited the mobility shift observed in hydroxyurea-treated cells (Fig 1G, lanes 9 and 10). We concluded that while Ser 6 is the single target of CDK, Ser 114 and Thr 115 are the direct or indirect targets of the Cds1 pathway. We demonstrated a physical interaction between MBF and Yox1 in asynchronously growing cells (supplementary Fig S1C,D online), but when Yox1 was phosphorylated as a consequence of the activation of the DNA synthesis checkpoint after hydroxyurea treatment, this interaction was lost (Fig 2A, lanes 5 and 6; Fig 2B). Nevertheless, this interaction was preserved in cells in which this Cds1-dependent phosphorylation was abrogated, because they expressed a mutant Yox1 that cannot be phosphorylated (Yox1.SATA; Fig 2A, lanes 7 and 8).

Although single mutations (Yox1.SA or Yox1.TA) had a strong effect on Yox1 mobility (Fig 1G), the effect on MBF-dependent transcription after hydroxyurea treatment was minor. However, Yox1.SATA cells had severely impaired MBF-dependent induction of transcription when treated with hydroxyurea (Fig 2C,D), without affecting the normal cell-cycle regulation of MBF-dependent genes (supplementary Fig S5 online). Thus, Yox1 phosphorylation on Ser 114 and Thr 115 was the single event required to activate MBF-dependent transcription when the checkpoint was activated until DNA synthesis machinery was replenished with deoxynucleotides. Concomitantly with the loss of interaction between Yox1 and MBF after treatment with hydroxyurea, Yox1 is evicted from cdcc18 and cdcc22 promoters, as measured by chromatin immunoprecipitation (ChIP) experiments (Fig 2E). This release from chromatin was diminished in Yox1.SATA cells and absent in rad3 cells, in which the checkpoint pathway is completely abolished. Next, we wanted to know whether fission yeast cells that expressed a mutant Yox1 that cannot be phosphorylated (Yox1.SATA) were sensitive to hydroxyurea. Surprisingly, Yox1.SATA cells behaved exactly as wild-type cells (Fig 2F and data not shown), indicating that, at least in wild-type cells, maintenance of MBF gene expression by Cds1 is not crucial to the replication checkpoint response. This led us to investigate what would happen in cells with a shorter G2 phase that were growing in the presence of hydroxyurea. Wild-type S. pombe cells spend most of their time in G2 phase, which could compensate for the lack of induction of MBF-dependent transcription observed in the Yox1.SATA cells, preventing aberrant mitosis. Consequently, in a wee1-50 background—which has a shorter G2 phase as they have an advanced G2–M transition—Yox1.SATA cells showed hypersensitivity to hydroxyurea (Fig 2F, compare

**Fig 3** Nrm1 loads Yox1 onto MBF-dependent genes. (A) Total RNA was prepared from untreated (−) or HU-treated (+) cultures of wild-type (wt) and 
yox1, nrm1 and 
yox1 nrm1 cells, and analysed by hybridization to the probes indicated on the right. tbf2 and rRNA are shown as loading control. (B) Loading of Yox1 (left panel) or Nrm1 (right panel) on 
and 
producers was measured by ChIP in untreated or HU-treated (+ HU) cultures of wt nrm1 and 
yox1 cells. The average of four experiments (± s.d.) is plotted. (C) Loading of Yox1 or Cdc10 on 
and 
producers was measured in untreated or HU-treated (+ HU) cultures of wt and Yox1.SATA (SATA) cells by ChIP. The average of three experiments (± s.d.) is plotted. ChIP, chromatin immunoprecipitation; HU, hydroxyurea; MBF, Mlu1 binding factor.
Yox1 binding to MBF is dependent on Nrm1

Yox1 was responsible for the repression of MBF-dependent transcription at the end of S phase (Aligianni et al., 2009). A similar role has previously been shown for Nrm1 (de Bruin et al., 2008). To determine whether these proteins had an overlapping role in the regulation of MBF-dependent transcription, we prepared RNA from wild-type, Δyox1, Δnrm1 and Δyox1 Δnrm1 cells, either from asynchronous cultures or from cells treated with hydroxyurea. As shown in Fig 3A, we found similar constitutive expression of MBF-dependent genes in Δyox1, Δnrm1 and Δyox1 Δnrm1 cells, measured by the amount of cdc18 mRNA. Next, we wanted to determine whether this effect correlated with the release of Yox1 and/or Nrm1 from chromatin, as measured by ChIP experiments. As shown in Fig 3B, both Yox1 and Nrm1 are cleared from cdc18 and cdc22 promoters when cells are treated with hydroxyurea. However, whereas Yox1 is dispensable for Nrm1 loading onto chromatin, Nrm1 is essential for Yox1 loading onto its MBF-target promoters (Fig 3A, compare Yox1 ChIP in Δnrm1 cells with Nrm1 ChIP in Δyox1 cells). Thus, in Δyox1 cells, Nrm1 is normally loaded onto MBF-target promoters and cleared on hydroxyurea treatment, but MBF-dependent transcription remains active in both the presence and absence of hydroxyurea (compare Fig 3A lanes 3–4 with Fig 3B). Finally, we measured Yox1 and Yox1.SATA release from chromatin when cells were treated with hydroxyurea (Fig 3C). Although cells expressing Yox1.SATA showed an impaired induction of cdc18 and cdc22 compared with wild-type cells (Fig 2C,D), we only detected a minor effect on Yox1.SATA retention in chromatin. However, Cdc10—and, probably, other components of the MBF complex—was partly ejected from chromatin when Yox1.SATA cells were treated with hydroxyurea (Fig 3C), which could account for the lack of induction of MBF-dependent genes observed in these cells (Fig 2C,D). All of these experiments indicate that the regulation of MBF-dependent transcription is highly complicated, with several layers of control including retention and/or release of the repressor (Yox1) or the transcription factor itself (Cdc10).

Previous reports have shown a link in mammalian cells between the DNA damage checkpoint and E2F/retinoblastoma, the functional homologue of yeast MBF (Stevens et al., 2003; Inoue et al., 2007; Zalmas et al., 2008). Here, we report a new mechanism that couples cell-cycle regulation and the DNA replication checkpoint, focusing on a single protein, Yox1. In a normal cell cycle, Nrm1 (de Bruin et al., 2008) loads the repressor Yox1 onto MBF-target genes and, together with Cig2 (Ayte et al., 2001), they are part of the mechanism by which MBF-dependent genes are repressed at the end of each S phase of the cell cycle (Fig 4). It remains to be clarified what is the role, if any, of the CDK phosphorylation of Yox1 on MBF-dependent transcription; so far, we have been unable to find any in vivo effect of Ser6 phosphorylation on MBF-dependent transcription. However, when DNA synthesis is compromised and the checkpoint is activated, Yox1 is phosphorylated by the effector kinase Cds1. As a result, transcription of MBF-dependent genes is active until DNA synthesis can be completed. Other reports have shown that Cds1 is able to phosphorylate other components of MBF, such as Cdc10 and Nrm1 (Dutta et al., 2008; de Bruin et al., 2008). However, Cdc10 and Nrm1 mutants that cannot be phosphorylated by Cds1 showed no significant defect in checkpoint regulation of transcription, whereas Yox1.SATA abolished this checkpoint regulation (Fig 2C,D), pointing to Yox1 as the main target of the Cds1 pathway. Interestingly, both the G1–S transition of a normal cell cycle and the DNA synthesis checkpoint (Cds1-dependent phosphorylation of Yox1) manage to activate MBF-dependent transcription, although to a different extent: the former induces a transient activation of transcription and the latter maintains the induction of MBF-dependent genes for as long as the checkpoint is active. A different question is whether Δyox1 cells have an advantage compared with wild-type cells in stress situations, why have they not been selected during evolution? The answer could be related to the increased genomic instability that we observed in Δyox1 cells (Fig 1B). Thus, Yox1 would be the nexus of a robust system to ensure that cells can respond to stress situations in which DNA synthesis is compromised, by using the same machinery that normally regulates cell-cycle-dependent transcription.

METHODS

Strains and media. All S. pombe strains are isogenic to wild-type 972h- and are listed in the supplementary information online.